Apel Daniel Joseph 4

What Happened Daniel J. Apel, Chief Financial Officer of Arrowhead Pharmaceuticals (ARWR), sold a total of 13,095 shares in open-market transactions on April 22, 2026, generating approximately $934,286 in proceeds. The sales were reported as three tranches: 3,208 shares at a weighted average price of $70.11 ($224,913), 1,157 shares at $70.45 ($81,511), and 8,730 shares at $71.92 ($627,862). These were dispositions (sales), not purchases.

Key Details

• Transaction date: 2026-04-22; Form 4 filed 2026-04-24 (appears within the standard 2-business-day filing window).
• Tranches and prices:
  • 3,208 shares @ $70.11 (weighted avg; actual prices ranged $69.50–$70.23) — $224,913. (Footnote F3)
  • 1,157 shares @ $70.45 (weighted avg; actual prices ranged $70.29–$70.51) — $81,511. (Footnote F5)
  • 8,730 shares @ $71.92 (weighted avg; actual prices ranged $71.55–$71.97) — $627,862. (Footnote F6)
• Reported total proceeds: ~$934,286.
• Notable footnotes: sales executed pursuant to a pre-established Rule 10b5-1 trading plan (F1); a partial disposition was used to satisfy tax withholding obligations (F2); some shares include previously reported RSU-related shares, a portion of which remain subject to vesting (F4).
• Shares owned after the transaction: not specified in the excerpt provided; see the full Form 4 for updated holdings.

Context

• These were planned sales under a 10b5-1 plan, which typically indicates pre-set instructions rather than discretionary trading at the time of sale—commonly viewed as routine rather than a direct signal about near-term company prospects.
• A portion of the disposition relates to tax withholding for RSUs, which is administrative (not a market-timing purchase or gift).
• No purchases, option exercises, or gifts were reported in this filing.